CD97/ADGRE5 attenuates the induction of adaptive type 2 immune responses in allergic asthma
- Gabriela Aust
- Anna-Lena Hoh
- Jehan Alladina
- Neal P. Smith
- Florian Höhna
- Bingyu Wang
- Christiane Kerner
- Marita Wagner
- Knut Krohn
- Arkadiusz Pierzchalski
- Nele Häussler
- Alexandra-Chloé Villani
- Josalyn L. Cho
- Benjamin D. Medoff
- Ana C. Zenclussen
- Matthias Steinert
- Jörg Hamann
- Marianne Quaas
- Tobias Polte
2026-08-27
Allergic asthma results from an uncontrolled type 2 immune response to inhaled allergens. Here, we investigate the function of CD97/ ADGRE5 , expressed in mouse and human immune and lung epithelial cells, in this disease. Female Cd97 −/− mice exhibit an exacerbated asthmatic phenotype across multiple models, primarily due to CD97 loss on immune cells. A single CD97 antibody treatment before allergen sensitization worsens allergic responses, highlighting a role for CD97 in early immune regulation. Post-sensitization, Cd97 −/− mice display higher frequencies of lung conventional type 2 and monocyte-derived dendritic cells (DCs). Allergen-pulsed Cd97 −/− bone marrow-derived DCs are more activated, promote enhanced proliferation and type 2 cytokine secretion by CD4⁺ OT-II cells, and induce stronger airway inflammation. Consistently, ADGRE5 expression is reduced in airway mucosa-derived mononuclear phagocyte subsets in human asthmatics after allergen-induced exacerbation. These results identify CD97 as an important regulator of DC-driven type 2 allergic responses and a potential target in asthma.